Holen Sie sich die Stockscreener-App
2.725
0.07%
0.005
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Aug Selloffs: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncMarket Risk Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncGDP Growth & Short-Term High Return Strategies - baoquankhu1.vn
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan
ABOS Technical Analysis & Stock Price Forecast - Intellectia AI
Meme Stocks: Is Acumen Pharmaceuticals Inc being accumulated by smart moneyPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure - TipRanks
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2025 Earnings Conference - 富途牛牛
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
Aug Final Week: Can Acumen Pharmaceuticals Inc reach resistance levels soon - baoquankhu1.vn
Acumen Pharmaceuticals (ABOS) Drops 33.6% Over the Past Month, Reasons Suggest a Potential Turnaround Could Be Imminent - Bitget
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen - MarketBeat
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program - Minichart
10.8M Acumen shares registered for resale (NASDAQ: ABOS) - stocktitan.net
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ: ABOS) details sabirnetug Alzheimer’s program and funding risks - Stock Titan
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
Stifel reiterates Acumen Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Acumen Pharmaceuticals stock rating at buy - Investing.com
Acumen Pharmaceuticals 2025 Financial Review - AlphaStreet
Acumen Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research - MarketBeat
Acumen Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ABOS: ALTITUDE-AD phase II and EBD advances drive robust pipeline and financial momentum - TradingView — Track All Markets
Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements By Investing.com - Investing.com South Africa
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements - Investing.com Canada
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ABOS: ALTITUDE-AD trial advances, EBD pipeline expands, and $35.75M raised for Alzheimer's innovation - TradingView
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating By Investing.com - Investing.com India
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update - ChartMill
Patterns Watch: What is the earnings history of Acumen Pharmaceuticals IncSell Signal & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - investing.com
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - Bitget
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative
1.36%
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):